Chemoprevention of Colon Carcinogenesis by Sulindac, a Nonsteroidal Anti-inflammatory Agent

Cancer Research

Volumn 55, Issue 7, 1995, Pages 1464-1472

  Rao, Chinthalapally V ^a   Rivenson, Abraham ^a   Simi, Barbara ^b   Zang, Edith ^b   Kelloff, Gary ^c   Steele, Vernon ^c   Reddy, Bandaru S ^d  

^a Pathology and Toxicology and Epidemiology ^*  (United States)

^b AMERICAN HEALTH FOUNDATION   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d Divisions of Nutritional Carcinogenesis ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZOXYMETHANE; LIPOXYGENASE; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHOLIPASE A2; PHOSPHOLIPASE C; PROSTAGLANDIN SYNTHASE; SULFONE DERIVATIVE; SULINDAC; SULINDAC SULFIDE; SULINDAC SULFONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARACHIDONIC ACID METABOLISM; ARTICLE; CANCER GROWTH; CANCER PREVENTION; COLON ADENOCARCINOMA; CONTROLLED STUDY; DRUG EFFICACY; DRUG SCREENING; DRUG STRUCTURE; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT;

ADENOCARCINOMA; ANIMAL; AZOXYMETHANE; COLONIC NEOPLASMS; DRUG SCREENING ASSAYS, ANTITUMOR; HYDROXYEICOSATETRAENOIC ACIDS; MALE; PHOSPHATIDYLINOSITOL 4,5-DIPHOSPHATE; PHOSPHATIDYLINOSITOL PHOSPHATES; PHOSPHOLIPASES A; PHOSPHORIC DIESTER HYDROLASES; PROSTAGLANDINS; RATS; RATS, INBRED F344; SULINDAC; SUPPORT, U.S. GOV'T, P.H.S.; THROMBOXANES; VEHICLES;

EID: 0028904461     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. Boring, C.C. Squires, T.S. Tong, T. and Montgomery, S. Cancer Statistics. CA-Cancer J. Clin. 44: 7-26, 1994.
2. Wynder, E.L. Kajitani, T. Ishikawa, S. Dodo, H. and Takano, A. Environmental factors of cancer of colon and rectum. II. Japanese epidemiological data. Cancer (Phila.), 23: 1210-1220, 1969.
3. National Research Council. Diet, Nutrition and Cancer, Assembly of life Sciences. Washington, DC: National Academy Press, 1982.
4. Miller, A.B. Howe, G.R. and Jain, M. Food items and food groups as risk factors in a case-control study of diet and colon cancer. Int. J. Cancer, 32: 155-162, 1983.
5. Reddy, B.S. Diet and colon cancer: evidence from human and animal model studies. In: B.S. Reddy and L.A. Cohen (eds.), Diet, Nutrition and Cancer: A Critical Evaluation, pp. 47-65. Boca Raton, FL: CRC Press, 1986.
6. Wattenberg, L.W. Chemoprevention of cancer by naturally occurring and synthetic compounds. In: L.W. Wattenberg, M. Lipkin, C.W. Boone, and G.J. Kelloff (eds.), Cancer Chemoprevention, pp. 19-39. Boca Raton, FL: CRC Press, 1992.
7. Kelloff, G.J. Boone, C.W. Malone, W.E. and Steele, V.E. Recent results in preclinical and clinical drug development of chemopreventive agents at the National Cancer Institue. In: L.W. Wattenberg, M. Lipkin, C.W. Boone, and G.J. Kelloff (eds.), Cancer Chemoprevention, pp. 41-56. Boca Raton, FL: CRC Press, 1992.
8. Marnett, L.J. Aspirin and potential role of prostaglandins in colon cancer. Cancer Res. 52: 5575-5589, 1992.
9. Smith, W.L. Prostanoid biosynthesis and mechanisms of action. Am. J. Physiol. 263: F181-F191, 1992.
10. Reddy, B.S. Rao, C.V. Rivenson, A. and Kelloff, G.J. Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. Carcinogenesis (Lond.), 14: 1493-1497, 1993.
11. Metzger, U. Meier, J. Uhlschmid, G. and Weihe, H. Influence of various prostglandin synthesis inhibitors on DMH-induced rat colon cancer. Dis Colon Rectum, 27: 366-369, 1984.
12. Narisawa, T. Satoh, M. Sano, M. and Takahashi, T. Inhibition of initiation and promotion on N-methylnitrosourea-induced colon carcinogenesis in rats by nonsteroidal anti-inflammatory agent indomethacin. Carcinogenesis (Lond.), 14: 1493-1497, 1993.
13. Pollard, M. and Luckert, P.H. Effect of piroxicam on primary intestinal tumors induced in rats by W-methylnitrosourea. Cancer Lett. 25: 117-121, 1984.
14. Reddy, B.S. Maruyama, H. and Kelloff, G. Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal anti-inflammatory drug, during different stages of rat colon tumor development. Cancer Res. 47: 5340-5346, 1987.
15. Moorghen, M. Ince, P. Finney, K.J. Sunter, J.P. Appleton, D.R. and Watson, A.J.A. A protective effect of sulindac against chemically-induced primary colonic tumors in mice. J. Pathol. 156: 341-347, 1988.
16. Klein, W.A. Miller, H.H. Anderson, M. and Decosse, J.J. The use of indomethacin, sulindac and tamoxifen for the treatment of desmoid tumors associated with familial polyposis. Cancer (Phila.), 60: 2863-2868, 1987.
17. Thun, M.H. Namboodiri, M.M. and Heath, C.W. Aspirin use and reduced risk of fatal colon cancer. N. Engl. J. Med. 325: 1593-1596, 1991.
18. Belliveau, P. and Graham, A.M. Mesenteric desmoid tumor in Gardener's syndrome treated by sulindac. Dis. Colon Rectum, 27: 53-54, 1984.
19. Waddel, R.W. Ganser, G.F. Cerise, E.J. and Loughry, R.W. Sulindac for polyposis of the colon. Am. J. Surg. 157: 175-179, 1989.
20. Laybayle, D. Fischer, D. Vielh, P. Frouhin, F. Pariente, A. Bories, C. Duhamael, O. Trousset, M. and Atti, P. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology, 101: 635-639, 1991.
21. Spagnesi, M.T. Tonelli, F. Dolara, P. Caderni, G. Valanzano, R. Anastasi, A. and Bianchini, F. Rectal proliferation and polyp occurrence in patients with familial adenomatous polyposis after sulindac treatment. Gastroenterology, 106: 362-366, 1994.
22. Winde, G. Gumbinger, H.G. Osswald, H. Kemper, F. and Bunte, H. The NSAID sulindac reverses rectal adenomas in colectomized patients with familial adenomatous polyposis: clinical results of a dose finding study on rectal sulindac administration. Int. J. Colored. Dis. 8: 13-17, 1993.
23. Giardello, F.M. Hamilton, S.R. Krush, A.J. Piantodosi, S. Hylind, L.M. Cleano, P. Booker, S.V. Robinson, R.C. and Offerhaus, G.J.A. Treatment of colonic rectal adenomas with sulindac in familial adenomatous polyposis. N. Engl. J. Med. 328: 1313-1316, 1993.
24. Skinner, S.A. Penney, A.G. and O'Brien, P.E. Sulindac inhibits the rate of growth and appearence of colon rumor in the rat. Arch. Surg. 126: 1094-1096, 1991.
25. Ahnen, D. Hixson, L. Alberts, D. Bogert, C. Einspahr, IC, Brendel, P. Gross, N. Paranlea, R. and Pamukeu, R. Sulindac and its sulfone metabolite (FGN-1) both inhibit rat colon carcinogenesis but neither inhibit colonic proliferation. Proc. Am. Assoc. Cancer Res. 35: 631, 1994.
26. Rigau, J. Pique, J.M. Rubio, E. Planas, R. Tarrech, J.M. and Bordas, J.M. Effect of long-term sulindac therpy on colonic polyposis. Ann. Intern. Med. 115: 952-954, 1991.
27. Marnett, L.J. (ed.). Arachidonic Acid Metabolism and Tumor Initiation. Boston: Martinus Nijhoff Publishing, 1985.
28. Honn, K.V. Bockman, R.S. and Marnett, L.J. Prostaglandins and cancer: a review of tumor initiation through tumor metastasis. Prostaglandins, 21: 864-883, 1981.
29. Bockman, R.S. Prostaglandins in cancer: a review. Cancer Invest. 1: 485-493, 1983.
30. Karmali, R.A. Esosanoids and cancer. Prog. Clin. Biol. Res. 222: 687-697, 1986.
31. Hokin, L.E. Receptors and phosphoinositide-generated second messengers. Annu. Rev. Biochem. 54: 205-235, 1985.
32. Parker, J. Daniel, L.W. and Waite, M. Evidence of protein kinase C involvement in phorbol diester-stimulated arachidonic acid release and prostaglandin biosynthesis. J. Biol. Chem. 262: 5385-5393, 1987.
33. Dennis, E.A. Rhee, S.G. Billah, M.M. and Hannun, Y.A. Role of phospholipases in generating lipid second messengers in signal tranduction. FASEB J. 5: 2068-2077, 1991.
34. Cantley, L.C. Auges, K.R. Carpenter, C. Duckworth, B. Graziani, A. Kepeller, R. and Soltoff, S. Oncogenes and signal transduction. Cell, 64: 281-302, 1991.
35. Perrella, F.W. Jankewies, R. An Dandrow, E.A. Phospholipase C from human melanoma: purification and characterization of phosphatidylinositol-selective enzyme. Biochim. Biophys. Acta, 1076: 209-241, 1991.
36. Arteaga, C.L. Johnson, M.D. Todderud, G. Coffey, R.J. Carpenter, G. and Page, D.L. Elevated content of the tyrosine kinase substrate phospholipase C-r-1 in primary human breast carcinomas. Proc. Natl. Acad. Sci. USA, 88: 10435-10439, 1991.
37. Soydan, A.S. Tavares, I.A. Weech, P.K. and Bennet, A. High molecular weight phospholipase A2: its occurrence and quantification in human gut cancer and normal mucosa. 3rd International Conference on Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation and Radiation Injury, Washington, DC, p. 66, 1993.
38. Reddy, B.S. and Sugie, S. Effect of different levels of
39. Rao, C.V. Rivenson, A. Katiwalla, M. Kelloff, G.J. and Reddy, B.S. Chemopreventive effect of oltipraz during different stages of experimental colon carcinogenesis induced by azoxymethane in male F344 rats. Cancer Res. 53: 2502-2506, 1993.
40. Pozharisski, K.M. Tumors of the intestines. In: V. Turcusov and V. Mohr (eds.), Pathology of Tumors in Laboratory Animals, Vol. 1, pp. 159-198. Lyon, France: IARC Publications, 1990.
41. Leslie, C.C. Macrophage phospholipase A2 specific for sn-2-arachidanic acid. Methods Enzymol. 187: 216-225, 1990.
42. Bleasdale, J.E. McGuire, J.C. and Bala, G.A. Measurement of phosphoinositide-specific phospolipase C activity. Methods Enzymol. 187: 226-237, 1990.
43. Rao, C.V. and Reddy, B.S. Modulating effect of amount and types of dietary fat on ornithine decarboxylase, tyrosine protein kinase and prostaglandins production during colon carcinogenesis in male F344 rats. Carcinogenesis (Lond.), 14: 1327-1333, 1993.
44. Fishcer, S.M. Baldwin, J.K. Jasheway, R.W. Patrick, K.E. and Cameron, G.S. Phorbol ester induction 8-lipoxygenase in inbred SENCAR (SSIN) but not C57BL/6J mice correlated with hyperplasia, edema, and oxidant generation by not ornithine decarboxylase induction. Cancer Res. 48: 658-664, 1988.
45. Rao, C.V. Desai, D. Simi, B. Kulkarni, N. Amin, S. and Reddy, B.S. Inhibitory effect of caffeic acid esters on azoxymethane-induced biochemical changes and aberrant crypt foci formation in rat colon. Cancer Res. 53: 4182-4188, 1993.
46. Huang M.T. Lysz, T. Ferraro, T. Abidi, T.F. Laskin, J.D. and Conney, A.H. Inhibitory effects of curcumin on in vitro lipoxygenase and cyclooxygenase activities in mouse epidermis. Cancer Res. 57: 813-819, 1991.
47. Rubio, C.A. Antitumoral activity of indomehtacin on experimental esophageal tumors. J. Natl. Cancer Inst. 72: 705-707, 1984.
48. Tanaka, T. Nishikawa, A. Mori, Y. Morishita, M. and Mori, H. Inhibitory effects of non-steroidal antiinflammatory drugs, piroxican and indomethacin, on 4-nitro-quinoline 1-oxide-induced tongue carcinogenesis in male ACI/N rats. Cancer Lett. 48: 177-182, 1989.
49. Takahashi, M. Furukawa, F. Toyoda, K. Sato, H. Hasegawa, R. Imaida, K. and Hayashi, Y. Effects of various prostaglandin synthesis inhibitors on pancreatic carcinogenesis in hamsters after initiation with W-nitrosobis(2-oxopropyl)amine. Carcinogenesis (Lond.), 11: 393-395, 1990.
50. Sakata, T. Hasegawa, R. Johansson, S.L. Zenser, T.V. and Cohen, S.M. Inhibition by aspirin of N-[4-(5-nitro-2-furyl)-2-thiazoly]fonnamide initiation and sodium saccharin promotion of urinary bladder carcinogenesis in male F344 rats. Cancer Res. 46: 3903-3906, 1986.
51. Taton, G. Servais, P. and Garland, P. Modulation by indomethacin or prostaglandin E2 of the incidence of diethylnitrosamine-induced glutamyltranspeptidase postive foci in rat liver. Jpn. J. Cancer Res. 81: 747-753, 1990.
52. McCormick, D.L. Madigan, M.J. and Moon, R.C. Modulation of rat mammary carcinogenesis by indomethacin. Cancer Res. 45: 1803-1808, 1985.
53. Murray, M.D. and Brater, D.C. Renal toxicity of the nonsteriodal antiinflammatory drugs. Annu. Rev. Pharmacol. Toxicol. 33: 435-465, 1993.
54. Bunning, R.D. and Barth, W.F. Sulindac. A potentially renal-sparing nonsteriodal antiinflammatory drug. JAMA, 248: 2864-2867, 1982.
55. Brogden, R.N. Heel, R.C. Speight, T.M. and Avery, G.S. Sulindac. A review of its pharmacological properties and therapeutic efficacy in rheumatic diseases. Drugs, 16: 97-114, 1978.
56. Brooks, P.M. and Day, R.O. Nonsteroidal antiinflammatory drugs-differences and similarities. N. Engl. J. Med. 324: 1716-1724, 1991.
57. Shen, T.Y. and Winter, G.A. Chemical and biological studies on indomethacin, sulindac and their analogues. Adv. Drug Res. 12: 90-245, 1977.
58. Honn, K.V. Gropssi, I.M. Steinert, B.W. Chopra, H. Onoda, J. Nelson, K.K. and Taylor, J.D. Lipoxygenase regulation of membrane expression of tumor cell glyco-proteins and subsequent metastasis. Adv. Prostaglandin Thromboxane Leukotriene Res. 19: 439-443, 1989.
59. Timer, J. Chen, Y.Q. Liu, B. Bazar, R. Taylor, J.D. and Honn, K.V. The lipoxygenase metabolite 12(5)-HETE promotes allb 03 integrin-mediated tumor-cell spreading on fibronectin. Int. J. Cancer, 52: 594-603, 1992.
60. Furstenberger, G. Schurich, B. Kaina, B. Petrusevska, R.T. Fuesning, N.E. and Marks, F. Tumor induction in initiated mouse skin by phorbol esters and methyl-methanesulfonate: correlation between chromosomal damage and conversion (“stage I of tumor promotion”) in vivo. Carcinogenesis (Lond.), 10: 749-752, 1989.
61. Bond, L. Hagege, J. Straer, J. Rondeau, E. Perez, J. and Ardailau, R. Reactive oxygen production by cultured rat glomeruler mcsangial cells during phagocytosis is associated with stimulation of lipoxygenase activity. J. Exp. Med. 158: 1836-1852, 1993.
62. Nishizuka, Y. The role of protein kinase C in cell surface signal transduction and tumor promotion. Nature (Lond.), 308: 639-698, 1984.
63. Tsukuda, K. Church, J.M. Jagelman, D.G. Fazio, V.W. McGannon, E. George, C.R. Shcroeder, T. Lavery, I. and Oakley, J. Non-cytotoxic drug therapy for intra-abdominal desmoid tumor in patients with familial adenomatous polyposis. Dis. Colon Rectum, 35: 29-33, 1992.
64. Dujovne, L.A. Ripperman, A. Vincek, W.C. Dobrinsua, M.R. Davies, R. 0. and Duggan, D.E. Enterohepatic circulation of sulindac and metabolites. Clin. Pharmacol. Ther. 33: 172-177, 1983.